Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study
Authors:
Open Access
- 27 June 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1182299
Abstract
Objective: Examine patients with locally advanced rectal cancer (LARC) with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) who received neoadjuvant immunotherapy (nIT), and compare the outcomes of those who chose a watch-and-wait (WW) approach after achieving clinical complete response (cCR) or near-cCR with those who underwent surgery and were confirmed as pathological complete response (pCR).Methods: LARC patients with dMMR/MSI-H who received nIT were retrospectively examined. The endpoints were 2-year overall survival (OS), 2-year disease-free survival (DFS), local recurrence (LR), and distant metastasis (DM). The efficacy of programmed cell death protein-1 (PD-1) inhibitor, immune-related adverse events (irAEs), surgery-related adverse events (srAEs), and enterostomy were also recorded.Results: Twenty patients who received a PD-1 inhibitor as initial nIT were examined. Eighteen patients (90%) achieved complete response (CR) after a median of 7 nIT cycles, including 11 with pCR after surgery (pCR group), and 7 chose a WW strategy after evaluation as cCR or near-cCR (WW group). Both groups had median follow-up times of 25.0 months. Neither group had a case of LR or DM, and the 2-year DFS and OS in each group was 100%. The two groups had similar incidences of irAEs (P=0.627). In the pCR group, however, 2 patients (18.2%) had permanent colostomy, 3 (27.3%) had temporary ileostomy, and 2 (18.2%) had srAEs.Conclusion: Neoadjuvant PD-1 blockade had high efficacy and led to a high rate of CR in LARC patients with dMMR/MSI-H. A WW strategy appears to be a safe and reliable option for these patients who achieve cCR or near-cCR after nIT.Keywords
Funding Information
- Yunnan Provincial Department of Education Science Research Fund Project (2022J0227)
- Yunnan Provincial Science and Technology Department (202201AY070001-149)
This publication has 57 references indexed in Scilit:
- Tumour-associated and non-tumour-associated microbiota in colorectal cancerGut, 2016
- Microbiota organization is a distinct feature of proximal colorectal cancersProceedings of the National Academy of Sciences, 2014
- Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal CancerDiseases of the Colon & Rectum, 2013
- Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal CancerJournal of Clinical Oncology, 2011
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon CancerJournal of Clinical Oncology, 2010
- Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trialThe Lancet Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Causes of Fecal and Urinary Incontinence After Total Mesorectal Excision for Rectal Cancer Based on Cadaveric Surgery: A Study From the Cooperative Clinical Investigators of the Dutch Total Mesorectal Excision TrialJournal of Clinical Oncology, 2008
- Prevalence of Male and Female Sexual Dysfunction Is High Following Surgery for Rectal CancerAnnals of Surgery, 2005
- Classification of Surgical ComplicationsAnnals of Surgery, 2004